Search:
Home CellSearch [Spacer] GeneSearch [Spacer] News & Events [Spacer] Contact Us
The CellSearch™ Circulating Tumor Cell (CTC) Test from Veridex is a simple blood test that captures and assesses CTCs to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer at any time. The test offers an objective, quantitative, real-time reading of tumor information so that oncologists can provide optimum care for their patients.

If you are a patient, click here
Benefits of CellSearch™

The CellSearch™ CTC Test is a simple blood test that provides1:

An independent predictor of survival
CTCs are proven to be a strong, independent predictor of Overall Survival (OS) and Progression Free Survival (PFS)
 
Greater insight than standard tests alone
As an adjunct to current standard testing methods, CTC assessment provides a more complete picture of patient prognosis
 
More informed decisions at any time
Serial monitoring of CTCs can indicate a significant change in prognosis as early as after the first treatment cycle and at each step of the way
 
When to use the CellSearch™ CTC Test
Order the test prior to initiation of therapy to get CTC baseline, then order repeat tests at follow-up visits to assess prognosis and to inform patient care decisions.
 

The CellSearch™ CTC Test results should be used in conjunction with all clinical information derived from diagnostic tests (e.g. imaging or laboratory tests), physical examination, and complete medical history, in accordance with appropriate management procedures.

1 Instructions for Use, Veridex, LLC

Click to play CellSearch™ Circulating Tumor Cell Test video
Click Here To Access Instructions For Use
Click Here To Learn more about the CellSearch™ System